upcoming catalysts.

stock is drifting lower with EOFY selling , likely from holders who bought the placement @ $1.50 or above that also.

Here are the upcoming catalysts. Which one can get us back to better, improving SP, rather than the constant selling?

I would think the US based ann's would do the trick....would be surprised if its still heading south on USA ann's. e.g. NFL one or the FDA one. those are a big deal.

Sellers are forgetting all this stuff coming:

The Companyhas now completed its $77.9m capital raising and is focused on delivering on its pipeline of catalysts for the remainder of 2019:•Further release of OApainresults under the TGA special access scheme throughout remainder of CY2019. Next batch of patients for release imminent. •Release of peer reviewed journal paper detailing mechanism of action of PPS via Nerve Growth Factor (NGF) –expected Q2 CY2019•Appointment of highly regarded US based CMO –Q2 CY2019•First SAS filing with the TGA for the treatment of MPS patients with iPPS –Q2 CY2019•Up to 50 ex-NFL players in the US to be treated with iPPS for OA pain -Potential for significant media attention if treatment is successful –FDA approval for compassionate use and dosing to begin Q2 CY2019, first results likely late Q3 CY2019•File IND for pivotal Phase 2/3 for Mucopolysaccharidosis (MPS) -Q2 CY2019•File TGA Provisional Approval to sell ZILUSOL®(iPPS) in Australia, potential for near term revenue –Q2 CY2019•Ross River Phase 2a (safety study) trial results release –Q2/Q3 CY2019•File IND and meet with FDA re Phase 3 trial in OA -Q3 CY2019•Possibility of being granted “Fast Track status” for Phase 3 OA trial